These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33683627)

  • 1. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.
    Moran M; Blum K; Ponce JV; Lott L; Gondré-Lewis MC; Badgaiyan S; Brewer R; Downs BW; Fynman P; Weingarten A; Cadet JL; Smith DE; Baron D; Thanos PK; Modestino EJ; Badgaiyan RD; Elman I; Gold MS
    Mol Neurobiol; 2021 Jul; 58(7):3335-3346. PubMed ID: 33683627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors.
    Gupta A; Bowirrat A; Gomez LL; Baron D; Elman I; Giordano J; Jalali R; Badgaiyan RD; Modestino EJ; Gold MS; Braverman ER; Bajaj A; Blum K
    Int J Environ Res Public Health; 2022 Jan; 19(1):. PubMed ID: 35010811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Benefits of Genetic Addiction Risk Score (GARS
    Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
    Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.
    Blum K; Chen ALC; Thanos PK; Febo M; Demetrovics Z; Dushaj K; Kovoor A; Baron D; Smith DE; Roy AK; Fried L; Chen TJH; Chapman E; Modestino EJ; Steinberg B; Badgaiyan RD
    Front Biosci (Elite Ed); 2018 Jan; 10(1):175-196. PubMed ID: 28930612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring opioid dependence in chronic pain patients: A comparison between addiction clinic and pain clinic patient populations.
    McDonough M; Johnson JL; White JM; Buisman-Pijlman FTA
    J Opioid Manag; 2019; 15(4):285-293. PubMed ID: 31637681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Pain, Chronic Opioid Addiction: a Complex Nexus.
    Salsitz EA
    J Med Toxicol; 2016 Mar; 12(1):54-7. PubMed ID: 26602212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?
    Campbell G; Bruno R; Lintzeris N; Cohen M; Nielsen S; Hall W; Larance B; Mattick RP; Blyth F; Farrell M; Degenhardt L
    Pain; 2016 Jul; 157(7):1489-1498. PubMed ID: 26963848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of chronic opioid therapy and recognizing addiction.
    Daum AM; Berkowitz O; Renner JA
    JAAPA; 2015 May; 28(5):23-7. PubMed ID: 25853674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations.
    Kahan M; Wilson L; Mailis-Gagnon A; Srivastava A;
    Can Fam Physician; 2011 Nov; 57(11):1269-76, e419-28. PubMed ID: 22084456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte opioid receptors as innovative biomarkers of osteoarthritic pain, for the assessment and risk management of opioid tailored therapy, before hip surgery, to prevent chronic pain and opioid tolerance/addiction development: OpMarkArt (Opioids-Markers-Arthroprosthesis) study protocol for a randomized controlled trial.
    Malafoglia V; Celi M; Muscoli C; Ilari S; Lauro F; Giancotti LA; Morabito C; Feola M; Tarantino U; Raffaeli W
    Trials; 2017 Dec; 18(1):605. PubMed ID: 29258584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Social and Functional Implications of High- Versus Low-Dose Opioids on Chronic Non-Cancer Pain.
    Denawa Y; Kurtz W; Conermann T
    Pain Physician; 2019 Jul; 22(4):401-411. PubMed ID: 31337176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1.
    Smith AH; Jensen KP; Li J; Nunez Y; Farrer LA; Hakonarson H; Cook-Sather SD; Kranzler HR; Gelernter J
    Mol Psychiatry; 2017 Mar; 22(3):346-352. PubMed ID: 28115739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone.
    Oaks Z; Stage A; Middleton B; Faraone S; Johnson B
    Discov Med; 2018 Nov; 26(144):197-206. PubMed ID: 30695679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addictive behaviors related to opioid use for chronic pain: a population-based study.
    Hjsted J; Ekholm O; Kurita GP; Juel K; Sjgren P
    Pain; 2013 Dec; 154(12):2677-2683. PubMed ID: 23906554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment.
    Dennis BB; Roshanov PS; Bawor M; Paul J; Varenbut M; Daiter J; Plater C; Pare G; Marsh DC; Worster A; Desai D; Thabane L; Samaan Z
    Pain Physician; 2016 Jan; 19(1):E181-95. PubMed ID: 26752486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-variant Genetic Panel for Genetic Risk of Opioid Addiction.
    Donaldson K; Demers L; Taylor K; Lopez J; Chang S
    Ann Clin Lab Sci; 2017 Aug; 47(4):452-456. PubMed ID: 28801372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing addiction to prescribed opioids: the job of general practice?
    Leach JM
    Br J Gen Pract; 2018 Sep; 68(674):426-427. PubMed ID: 30166381
    [No Abstract]   [Full Text] [Related]  

  • 18. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.